secwatch.observer — SEC 8-K summary
======================================

Issuer:     NKGen Biotech, Inc. (—)
CIK:        0001845459
Form:       8-K
Filed at:   2026-01-09T23:59:59+00:00
Accession:  0001213900-26-003030
Event type: debt
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NKGen Biotech enters $25.84M secured promissory note with AlpineBrook at 12% interest
--------------------------------------------------------------------------------

- Note principal $25,840,106; 12% interest; initial maturity 2 months, extendable at lender's sole discretion.
- Note documents $25,540,106 in prior advances plus $300,000 new cash; no prepayment without lender consent.
- Includes most-favored-nation clause; security interests in US personal/real property and NKGen Korea shares.
- Change of control triggers 20% prepayment premium; restrictive covenants limit additional debt and liens.
- Security interests subordinated to East West Bank and BDW Investments liens; Korean share pledge after July 2026 lock-up.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1845459/000121390026003030/0001213900-26-003030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1845459/000121390026003030/ea0272061-8k_nkgen.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-003030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer